Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects

Haemophilia

Volumn 20, Issue 3, 2014, Pages 398-406

  Valentino, L A ^a   Rusen, L ^b   Elezovic, I ^c   Smith, L M ^d   Korth Bradley, J M ^d   Rendo, P ^d  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Institutul National de Hematologie Transfuzionala   (Romania)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d PFIZER INC   (United States)

Author keywords

Factor IX; Haemophilia B; Prophylaxis; Recombinant factor IX

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9; RECOMBINANT PROTEIN;

ACCIDENTAL INJURY; ADULT; AGED; ARTHRALGIA; ARTICLE; BLEEDING; CHEMOPROPHYLAXIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; COUGHING; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HEADACHE; HEMAGGLUTINATION; HEMARTHROSIS; HEMOPHILIA B; HUMAN; INFECTION; INJECTION SITE BURNING; INTENTION TO TREAT ANALYSIS; KIDNEY PAIN; LOW BACK PAIN; MALE; MULTICENTER STUDY; OPEN STUDY; PAIN; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCROTAL PAIN; SIDE EFFECT; ADOLESCENT; CLINICAL TRIAL; MIDDLE AGED; PHASE 4 CLINICAL TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CROSS-OVER STUDIES; FACTOR IX; HEMOPHILIA B; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84898914046     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12344     Document Type: Article

References (30)

1. MASAC recommendation 170 concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). National Hemophilia Foundation, 2007. Available at http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=582. Accessed December 4, 2013.
2. Delivery of treatment for haemophilia. World Health Organization, 2002. Available at http://whqlibdoc.who.int/hq/2002/WHO_WFH_ISTH_WG_02.6.pdf. Accessed December 4, 2013.
3. Guidelines for the management of hemophilia. World Federation of Hemophilia, 2005. Available at http://www1.wfh.org/publication/files/pdf-1296.pdf. Accessed December 4, 2013.
4. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
5. Rocca A, Pizzinelli S, Oliovecchio E, Santagostino E, Rocino A, Iorio A. Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy. Blood Transfus 2011; 9: 60-9.
6. Summary Report of UDC Activity, National Treatment/Clinical Characteristics (Hemophilia). United States Centers for Disease Control and Prevention, 2011. Available at https://www2a.cdc.gov/ncbddd/htcweb/udc_report/udc_report.asp. Accessed December 4, 2013.
7. Aznar JA, Lucia JF, Abad-Franch L et al. Focusing on haemophilia B: prophylaxis in Spanish patients. Haemophilia 2011; 17: 542-3.
8. Biss TT, Chan AK, Blanchette VS, Iwenofu LN, Mclimont M, Carcao MD. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 2008; 14: 923-30.
9. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
10. Morfini M, Mannucci PM, Mariani G et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scand J Haematol 1976; 16: 41-7.
11. Tagliaferri A, Rivolta GF, Rossetti G, Pattacini C, Gandini G, Franchini M. Experience of secondary prophylaxis in 20 adolescent and adult Italian hemophiliacs. Thromb Haemost 2006; 96: 542-3.
12. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
13. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2006; 2: CD003429.
14. White GC. Parachutes and prophylaxis: they both work! J Thromb Haemost 2006; 4: 1226-7.
15. Charlebois TS, O'Connell BD, Adamson SR et al. Viral safety of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38: 32-9.
16. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients-a long-term follow-up. J Intern Med 1997; 241: 395-400.
17. Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol 2012; 88: 329-35.
18. Shapiro AD, Di Paola J, Cohen A et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005; 105: 518-25.
19. Lambert T, Recht M, Valentino LA et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007; 13: 233-43.
20. Monahan PE, Liesner R, Sullivan ST, Ramirez ME, Kelly P, Roth DA. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B. Haemophilia 2010; 16: 460-8.
21. Kisker CT, Eisberg A, Schwartz B. Prophylaxis in factor IX deficiency product and patient variation. Haemophilia 2003; 9: 279-84.
22. Ewenstein BM, Joist JH, Shapiro AD et al. Pharmacokinetic analysis of plasma-derived and recombinant FIX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion (Paris) 2002; 42: 190-7.
23. Chang HH, Yang YL, Hung MH, Tsay W, Shen MC. Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan. J Formos Med Assoc 2007; 106: 281-7.
24. Bjorkman S. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. Haemophilia 2011; 17: 179-84.
25. Korth-Bradley JM, Valentino LA, Rendo P et al. Pharmacokinetic/pharmacodynamic assessment of reformulated recombinant coagulation factor IX in adults and children with severe hemophilia B [abstract]. Presented at: 53rd Annual Meeting of the American Society of Hematology; San Diego, CA: December 10-13, 2011.
26. Valentino LA. Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? Haemophilia 2004; 10: 147-57.
27. Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.
28. Santagostino E. Prophylaxis in haemophilia B patients: unresolved issues and pharmacoeconomic implications. Haemophilia 2010; 16(Suppl. 6): 13-7.
29. Tagliaferri A, Franchini M, Coppola A et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14: 945-51.
30. Rendo P, Shafer FE, Charnigo RJ et al. One-year assessment of coagulation markers and monitoring for thrombotic eventsin hemophilia B patients treated with nonacog alfa [abstract]. Presented at: World Federation of Hemophilia World Congress; Paris, France: July 8-12, 2012.